Share
David Stevens
Kindeva, a global contract development and manufacturing organization (CDMO) and innovator in drug delivery solutions, has announced a series of planned leadership transitions aimed at accelerating growth across its core parenteral and inhaled drug delivery businesses.
David Stevens, previously President of Kindeva, has assumed the role of Chief Executive Officer. With a strong track record of building high-performing teams and leading organizations through periods of significant growth and capacity expansion, Stevens is well positioned to guide Kindeva’s next phase of innovation and operational scale. His leadership will support continued investment in advanced drug delivery technologies and the expansion of strategic partnerships that enhance patient outcomes.
These leadership changes conclude a structured succession plan initiated in October 2025 and reflect Kindeva’s commitment to stability, continuity, and sustained value creation. The transition reinforces the company’s focus on strengthening its core capabilities while positioning Kindeva for long-term success in the evolving global pharmaceutical landscape
